10/15 -17, 2009; North American Cystic Fibrosis Conference, Minneapolis, MN

• Poster # 364: Antimicrobial Activity of Nanoemulsions Against Clinical Isolates from Cystic Fibrosis Patients

9/12-15, 2009; Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Francisco, California. 

• Poster # G1-877: Intranasal W805EC Adjuvanted Fluzone Provides Robust Immunity and Cross-protection in Ferrets
• Poster # G1-878: A GLP Toxicity and Immunogenicity Study of NB-1008, an Intranasal W805EC-Adjuvanted-Fluzone Vaccine

8/17 -19, 2009; Immunotherapeutics & Vaccine Summit, Providence, RI. 

• W805EC, A Novel Nanoemulsion Adjuvant, enhances the Immune Response to Commercial Influenza Vaccines Following Nasal Administration in Ferrets

7/29 - 8/2, 2009; AAD Annual Summer Meeting, Boston, MA

• Poster # 106: Susceptibility of Propionibacterium acnes in the Presence of Sebum to NB-003
• Poster # 109: Novel Follicular-Targeted Nanoemulsions for Acne

5/6-9, 2009; Annual Conference, Society of Investigative Dermatology

• Poster # 464: In-vitro Skin Penetration of Novel Antimicrobial Nanoemulsion Formulations Containing Antifungal Agents
• Poster # 616: In-vitro Susceptibility of Propionibacterium acnes and Skin Penetration of NB-00X Formulations  

Saturday, May 9, 2009

• Poster # 465: Lateral Diffusion of Terbinafine Hydrochloride in a Novel Nanoemulsion

4/27-29, 2009, National Foundation for Infectious Diseases (NFID), 12th Annual Conference on Vaccine Research

• Poster # 166, 10:00 AM - 11:30 AM - W80/5EC Administration of NanoStat™ Adjuvanted Influenza Vaccine in Mice
• Oral Presentation # 165, 3:30 PM - 5:00 PM - W80/5EC, a Nanoemulsion Adjuvant Provides Robust Anti-influenza Immunity in Ferrets after a Single Immunization

Wednesday, April 29, 2009

• Oral Presentation: #179, 10:30 AM - 12:00 PM - Mucosal Vaccination with a Recombinant H5 Antigen and Nanoemulsion Adjuvant Potentiates Immune Response against Pandemic Avian Influenza

3/6-10, 2009, AAD Annual Meeting, San Francisco, California

• Poster # P2411: Antifungal Activity and Mechanism of Action of NB-002, a Novel Topical Antifungal, Against the Major Pathogens of Onychomycosis
• Poster # P2423: Antifungal Activity of NB-002, a Topical Nanoemulsion, against Rare Fungal Pathogens of Onychomycosis
• Poster # P2505: Investigator Assessed Time to Healing in a Randomized, Double-Blind, Vehicle Controlled Trial of a Novel Antiviral Nanoemulsion (NB-001) for Recurrent Herpes Labialis
• Poster # P2517: Safety, Tolerability and Pharmacokinetics of Topical NB-001 (0.1%,  0.3% and 0.5%) for the Treatment of Recurrent Herpes Labialis

• Poster # P2114: A Randomized, Double-blind, Vehicle-Controlled Trial of Novel Topical Antifungal Nanoemulsion (NB-002) in Subjects with Distal Subungual Onychomycosis

11/16-20, 2008, The American Association of Pharmaceutical Scientists (AAPS) Annual Meeting, Atlanta Georgia

• Poster # T3030: Lateral Diffusion of a Novel Anti-fungal Nanoemulsion In-vitro Human Cadaver Skin
• Poster # T3031: In-vitro Skin Permeation of Novel Antimicrobial Nanoemulsion Formulations
• Poster # T3310: Pharmacokinetics of a Novel Topical Antimicrobial Nanoemulsion

• Poster # W5239: Long Term Stability of NB-001: A novel Anti-viral Nanoemulsion

10/25-28, 2008, ICAAC / IDSA Joint Meeting, Washington, DC - NanoBio presented eight scientific posters and one oral presentation:

• NanoBio 2008 ICAAC / IDSA Presentations

9/28-10/1, 2008, IABS International Scientific Workshop: New Cells for New Vaccines:

• Presentation: Nanoemulsions: New, Non-inflammatory Mucosal Adjuvants

8/13-15, 2008, The Immunotherapeutics & Vaccine Summit, Novel Vaccines

• Presentation: Nanoemulsion-Based Vaccines are Safe Adjuvants that Deliver Antigens to Mucosal Surfaces
  

5/5-7, 2008, Annual Conference on Vaccine Research

• Presentation: A Novel Nanoemulsion Adjuvant Enhancing The Immune Response from Intranasal Influenza Vaccine in Mice

2/1-4, 2008, AAD Annual Meeting:

• Poster # 1801: Safety, Tolerance, Pharmacokinetics and Efficacy of Topical Nanoemulsion (NB-001) for the Treatment of Herpes Labialis
• Poster # 1410: Safety, Tolerance, and Pharmacokinetics of Topical Nanoemulsion (NB-002) for the Treatment of Onychomycosis
• Poster # 1815: Development of a Novel Antiviral Drug (NB-001) for Topical Application in Humans
• Poster # 1709: Development of a Novel Topically Applied Antifungal Agent (NB-002) Based on Nanoemulsion Technology

9/17–20, 2007, ICAAC Annual Meeting:

• Poster # M-1819: Antifungal Drugs Tolerability, Safety and Pharmacokinetics of Topical Nanoemulsions (NB-002) in Patients with Onychomycosis

12/16-19, 2005, ICAAC Annual Meeting:

• Poster Presentation: A Randomized Controlled Phase II Clinical Trial Demonstrating the Efficacy of Topical Nanoemulsions (NB-001)for the Treatment of Herpes Labialis